Schoedel KA - Search Results

1

Abuse potential assessment of cannabidiol (CBD) in recreational polydrug users: A randomized, double-blind, controlled trial.

Schoedel KA, Szeto I, Setnik B, Sellers EM, Levy-Cooperman N, Mills C, Etges T, Sommerville K. Schoedel KA, et al. Epilepsy Behav. 2018 Nov;88:162-171. doi: 10.1016/j.yebeh.2018.07.027. Epub 2018 Oct 2. Epilepsy Behav. 2018. PMID: 30286443 Free article. Clinical Trial.

2

Abuse liability assessment of eslicarbazepine acetate in healthy male and female recreational sedative users: A Phase I randomized controlled trial.

Levy-Cooperman N, Schoedel KA, Chakraborty B, Blum D, Cheng H. Levy-Cooperman N, et al. Among authors: schoedel ka. Epilepsy Behav. 2016 Aug;61:63-71. doi: 10.1016/j.yebeh.2016.05.010. Epub 2016 Jun 15. Epilepsy Behav. 2016. PMID: 27315134 Free article. Clinical Trial.

3

Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Crossover Study Evaluating the Abuse Potential of the Antiepileptic Drug Lacosamide in Healthy Recreational Drug Users.

Schoedel KA, Andreas JO, Doty P, Eckhardt K, Sellers EM. Schoedel KA, et al. J Clin Psychopharmacol. 2017 Dec;37(6):675-683. doi: 10.1097/JCP.0000000000000780. J Clin Psychopharmacol. 2017. PMID: 28926353 Clinical Trial.

4

Human abuse potential of brivaracetam in healthy recreational central nervous system depressant users.

Schoedel KA, Stockis A, Sellers EM. Schoedel KA, et al. Epilepsy Behav. 2018 Jan;78:194-201. doi: 10.1016/j.yebeh.2017.09.008. Epub 2017 Nov 15. Epilepsy Behav. 2018. PMID: 29153631 Clinical Trial.

5

Identification of Optimal Measures of Human Abuse Potential: A Post Hoc Assessment of 19 Studies.

Shram MJ, Levy-Cooperman N, Ratcliffe S, Mills C, Bartlett C, Chen N, Setnik B, Sellers EM, Schoedel KA. Shram MJ, et al. Among authors: schoedel ka. J Clin Psychopharmacol. 2020 Nov/Dec;40(6):568-578. doi: 10.1097/JCP.0000000000001302. J Clin Psychopharmacol. 2020. PMID: 33086237

6

Assessment of the abuse liability of a dual orexin receptor antagonist: a crossover study of almorexant and zolpidem in recreational drug users.

Cruz HG, Hoever P, Chakraborty B, Schoedel K, Sellers EM, Dingemanse J. Cruz HG, et al. CNS Drugs. 2014 Apr;28(4):361-72. doi: 10.1007/s40263-014-0150-x. CNS Drugs. 2014. PMID: 24627301 Clinical Trial.

7

Intranasal abuse potential of an abuse-deterrent oxycodone formulation compared to oxycodone immediate release and placebo in nondependent, recreational opioid users.

Setnik B, Schoedel K, Bartlett C, Dick C, Hakim N, Geoffroy P. Setnik B, et al. J Opioid Manag. 2017 Nov/Dec;13(6):449-464. doi: 10.5055/jom.2017.0421. J Opioid Manag. 2017. PMID: 29308591 Clinical Trial.

8

The role of adverse events and related safety data in the pre-market evaluation of drug abuse potential.

Mansbach RS, Schoedel KA, Kittrelle JP, Sellers EM. Mansbach RS, et al. Among authors: schoedel ka. Drug Alcohol Depend. 2010 Dec 1;112(3):173-7. doi: 10.1016/j.drugalcdep.2010.07.001. Drug Alcohol Depend. 2010. PMID: 20817417

9

Positive and negative subjective effects of extended-release oxymorphone versus controlled-release oxycodone in recreational opioid users.

Schoedel KA, McMorn S, Chakraborty B, Potts SL, Zerbe K, Sellers EM. Schoedel KA, et al. J Opioid Manag. 2011 May-Jun;7(3):179-92. doi: 10.5055/jom.2011.0061. J Opioid Manag. 2011. PMID: 21823549 Clinical Trial.

10

Randomized open-label drug-drug interaction trial of dextromethorphan/quinidine and paroxetine in healthy volunteers.

Schoedel KA, Pope LE, Sellers EM. Schoedel KA, et al. Clin Drug Investig. 2012 Mar 1;32(3):157-69. doi: 10.2165/11599870-000000000-00000. Clin Drug Investig. 2012. PMID: 22283559 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

42 results

Search Page

Filters